Frontier IP Group - Cambridge Raman participates in EUR 5m project
Frontier IP Group plc
("Frontier IP" or the "Group")
Portfolio news - Cambridge Raman Imaging participates in €5 million project to develop breakthrough medical imaging technology
Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Cambridge Raman Imaging Limited (the "Company") is part of CRIMSON, a
The technology combines advanced laser techniques and artificial intelligence to show how diseases unfold in cells and tissue at a molecular level in near real time. Initial applications include a microscope aimed at biomedical researchers, with initial validation work focused on cancer.
Over the next three-and-a-half years, CRIMSON aims to develop devices that are faster and more accurate than existing technologies to provide highly-detailed digital images of cells and tissue. The speed of the technology will allow researchers to use time-lapse imaging to observe how cells change when affected by disease without the presence of a dye or other chemicals.
Cambridge Raman Imaging is one of a 10-strong consortium involved in the project. The project is being led by its partner, the Politecnico di
Frontier IP Chief Executive Officer
CRIMSON statement begins:
European consortium to build next-generation microscope
promising to revolutionize the study of the cellular origin of diseases.
A breakthrough in microscopy and endoscopy will soon revolutionize the study of the cellular origin of diseases, advancing the field of precision medicine. This is the goal of CRIMSON, a trans-disciplinary and trans-national research project recently funded by European Commission. It will develop the next-generation bio-photonics imaging device for biomedical research, combining advanced laser techniques with artificial-intelligence data analysis. This groundbreaking microscope will provide three-dimensional quantitative maps of sub-cellular compartments in living cells and organoids and enable fast tissue classification with unprecedented biomolecular sensitivity. High acquisition speed will allow the observation of intra and inter-cellular dynamic changes by time-lapse imaging.
The CRIMSON project, starting
A multidisciplinary team of world-leading organizations with vertical integration of all required skills composes the consortium, coordinated by Politecnico di
Four innovative SMEs (Active Fibre Systems GmbH -
More info on www.crimson-project.eu
CRIMSON statement ends
Frontier IP Group Plc
T: 020 7332 2338
Company website: www.frontierip.co.uk
M: 07464 546 025
Allenby Capital Limited (Nominated Adviser)
T: 0203 328 5656
ABout frontier IP
Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Quick facts: Frontier IP Group PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE